BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31684984)

  • 1. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
    Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
    Yuan G; Chen X; Liu Z; Wei W; Shu Q; Abou-Hamdan H; Jiang L; Li X; Chen R; Désaubry L; Zhou F; Xie D
    J Exp Clin Cancer Res; 2018 Feb; 37(1):21. PubMed ID: 29415747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity.
    Qureshi R; Yildirim O; Gasser A; Basmadjian C; Zhao Q; Wilmet JP; Désaubry L; Nebigil CG
    PLoS One; 2015; 10(11):e0141826. PubMed ID: 26536361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
    Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.
    Islam S; Qi W; Morales C; Cooke L; Spier C; Weterings E; Mahadevan D
    Mol Cancer Ther; 2017 Oct; 16(10):2083-2093. PubMed ID: 28615297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
    Doudican NA; Orlow SJ
    Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer.
    Cao Y; Liang H; Zhang F; Luan Z; Zhao S; Wang XA; Liu S; Bao R; Shu Y; Ma Q; Zhu J; Liu Y
    J Exp Clin Cancer Res; 2016 Apr; 35():68. PubMed ID: 27084680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling.
    Jackson DN; Alula KM; Delgado-Deida Y; Tabti R; Turner K; Wang X; Venuprasad K; Souza RF; Désaubry L; Theiss AL
    Cancer Res; 2020 Sep; 80(17):3519-3529. PubMed ID: 32665357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
    Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
    Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
    Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
    Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas.
    Sarosiek KA; Malumbres R; Nechushtan H; Gentles AJ; Avisar E; Lossos IS
    Blood; 2010 Jan; 115(3):570-80. PubMed ID: 19965678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.